Pancreas Adenocarcinoma, Pancreas Cancer
Conditions
Brief summary
PaCaReg is a multicenter registry trial aiming in the assessement of clinical, epidemiological and biological profiles in patients with pancreatic ductal adenocarcinoma
Interventions
None listed
Sponsors
University of Ulm
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Treatment naive histologically or cytologically proven pancreatic ductal adenocarcinoma (PDAC) or highly suspicious diagnosis (only pre-curative-intended resection) * Age =\>18 years * written informed consent
Exclusion criteria
* papillary cancer * neuroendocrine pancreatic tumors
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| General assessment of applied therapy modalities in pancreatic cancer | First diagnose to death or end of surveillance (5 years after curative resection) | — |
| Quality of life in pancreatic cancer patients | First diagnose to death or end of surveillance (5 years after curative resection) | EORTC QLQ c30 and PAN 26 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| General epidemiologic assessment | First diagnose to death or end of surveillance (5 years after curative resection) | Epidemiologic questionaire |
| Assessment of tumor surveillance in pancreatic cancer patients | First diagnose to death or end of surveillance (5 years after curative resection) | — |
| Evaluation of predictive and prognostic markers | First diagnose to death or end of surveillance (5 years after curative resection) | — |
Countries
Germany
Contacts
Primary ContactThomas Seufferlein, MD
Outcome results
None listed